TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students
Brief Summary: The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tract infection (URTI) in students attending McMaster University. Investigators hypothesize that

1. Vitamin D3 supplementation will decrease the incidence of symptomatic upper respiratory tract infections in university students
2. Gargling will decrease the incidence of symptomatic upper respiratory tract infections in university students.


Options:
A: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
B: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
C: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students
Brief Summary: The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tract infection (URTI) in students attending McMaster University. Investigators hypothesize that

1. Vitamin D3 supplementation will decrease the incidence of symptomatic upper respiratory tract infections in university students
2. Gargling will decrease the incidence of symptomatic upper respiratory tract infections in university students.


Options:
A: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
B: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
C: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm
D: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students
Brief Summary: The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tract infection (URTI) in students attending McMaster University. Investigators hypothesize that

1. Vitamin D3 supplementation will decrease the incidence of symptomatic upper respiratory tract infections in university students
2. Gargling will decrease the incidence of symptomatic upper respiratory tract infections in university students.


Options:
A: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
B: Arm Label: Intervention Nursing Homes; Type: EXPERIMENTAL; Interventions: Other: Prevention of infections program | Arm Label: Usual care Nursing Homes; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prevention of infections program; Assigned to Arm(s): Intervention Nursing Homes
C: Arm Label: Medical Mask; Type: EXPERIMENTAL; Interventions: Device: Medical Mask | Arm Label: N95 respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 respirator | Intervention Type: DEVICE; Name: Medical Mask; Assigned to Arm(s): Medical Mask | Intervention Type: DEVICE; Name: N95 respirator; Assigned to Arm(s): N95 respirator
D: Arm Label: Green tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea | Arm Label: water; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: green tea | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea; Assigned to Arm(s): Green tea, water

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students
Brief Summary: The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tract infection (URTI) in students attending McMaster University. Investigators hypothesize that

1. Vitamin D3 supplementation will decrease the incidence of symptomatic upper respiratory tract infections in university students
2. Gargling will decrease the incidence of symptomatic upper respiratory tract infections in university students.


Options:
A: Arm Label: Placebo + Inactivated Influenza Vaccine (IIV); Type: ACTIVE_COMPARATOR; Interventions: Biological: IIV, Other: Placebo | Arm Label: MEDI7510 + IIV; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510, Biological: IIV | Intervention Type: BIOLOGICAL; Name: MEDI7510; Assigned to Arm(s): MEDI7510 + IIV | Intervention Type: BIOLOGICAL; Name: IIV; Assigned to Arm(s): MEDI7510 + IIV, Placebo + Inactivated Influenza Vaccine (IIV) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Inactivated Influenza Vaccine (IIV)
B: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
C: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
D: Arm Label: SynGEM low dose; Type: EXPERIMENTAL; Interventions: Biological: SynGEM | Arm Label: SynGEM high dose; Type: EXPERIMENTAL; Interventions: Biological: SynGEM | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: BIOLOGICAL; Name: SynGEM; Assigned to Arm(s): SynGEM high dose, SynGEM low dose | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome
Brief Summary: This will be the first study of the effect of essential fatty acid supplementation in pregnant women living in inner-city poverty on the stress response system during pregnancy. The investigators proposed that essential fatty acid supplementation will be associated with reductions in the experience of stress, more modulated hormonal response to stress, and more optimal regulation of emotion and attention in the infant, even within the context inner-city poverty.


Options:
A: Arm Label: 200 mg/day DHA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Docosahexaenoic acid - 200mg/day, Other: Placebo | Arm Label: 1000 mg/day DHA; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic acid - 800mg/day, Drug: Docosahexaenoic acid - 200mg/day | Intervention Type: DRUG; Name: Docosahexaenoic acid - 800mg/day; Assigned to Arm(s): 1000 mg/day DHA | Intervention Type: DRUG; Name: Docosahexaenoic acid - 200mg/day; Assigned to Arm(s): 1000 mg/day DHA, 200 mg/day DHA | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 200 mg/day DHA
B: Arm Label: DHA supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Docosahexanoic Acid | Arm Label: Soybean Oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosahexanoic Acid; Assigned to Arm(s): DHA supplementation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Soybean Oil
C: Arm Label: Omega-3 Fish Oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fish Oil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fish Oil; Assigned to Arm(s): Omega-3 Fish Oil, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Health Information Technology to Improve Healthcare Quality in Primary Care Practices and in Transitions Between Care Settings
Brief Summary: This study will test the effectiveness of clinician-focused health IT-based decision support, family-focused health IT-based decision support, and a combination of both efforts, in increasing HPV and other adolescent vaccine rates among adolescent girls. We hypothesize that a combination of clinician-focused clinical decision support and family-focused decision support will be most effective.


Options:
A: Arm Label: mHealth midwives; Type: EXPERIMENTAL; Interventions: Device: mHealth | Arm Label: mHealth midwives - control; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Arm Label: Pregnant Women; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Intervention Type: DEVICE; Name: mHealth; Assigned to Arm(s): Pregnant Women, mHealth midwives, mHealth midwives - control
B: Arm Label: Family Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support | Arm Label: Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Clinician Decision Support | Arm Label: Family DS+ Clinician DS; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support, Behavioral: Clinician Decision Support, Other: Family Decision Support and Clinician Decision Support | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Family Decision Support; Assigned to Arm(s): Family DS+ Clinician DS, Family Decision Support | Intervention Type: BEHAVIORAL; Name: Clinician Decision Support; Assigned to Arm(s): Clinical Decision Support, Family DS+ Clinician DS | Intervention Type: OTHER; Name: Family Decision Support and Clinician Decision Support; Assigned to Arm(s): Family DS+ Clinician DS | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIT Intervention without feedback; Type: EXPERIMENTAL; Interventions: Other: 3-Part Intervention | Arm Label: HIT Intervention with feedback; Type: EXPERIMENTAL; Interventions: Other: 4-Part Intervention | Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Other: 1-part intervention | Intervention Type: OTHER; Name: 3-Part Intervention; Assigned to Arm(s): HIT Intervention without feedback | Intervention Type: OTHER; Name: 4-Part Intervention; Assigned to Arm(s): HIT Intervention with feedback | Intervention Type: OTHER; Name: 1-part intervention; Assigned to Arm(s): Feedback only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥28 Weeks to ≤44 Weeks Gestational Age
Brief Summary: The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks gestational age, administered as a loading dose followed by a continuous infusion for a minimum of 6 hours and up to 24 hours in the neonatal intensive care unit (NICU), cardiac intensive care unit (CICU), or pediatric intensive care unit (PICU).


Options:
A: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
B: Arm Label: Dexmedetomidine 0.05 mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Drug: Fentanyl/Morphine, Drug: Dexmedetomidine | Arm Label: Dexmedetomidine 0.1 mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Drug: Fentanyl/Morphine, Drug: Dexmedetomidine | Arm Label: Dexmedetomidine 0.2 mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: Midazolam, Drug: Fentanyl/Morphine, Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Dexmedetomidine 0.05 mcg/kg, Dexmedetomidine 0.1 mcg/kg, Dexmedetomidine 0.2 mcg/kg | Intervention Type: DRUG; Name: Fentanyl/Morphine; Assigned to Arm(s): Dexmedetomidine 0.05 mcg/kg, Dexmedetomidine 0.1 mcg/kg, Dexmedetomidine 0.2 mcg/kg | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine 0.05 mcg/kg, Dexmedetomidine 0.1 mcg/kg, Dexmedetomidine 0.2 mcg/kg
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine, Drug: Midazolam, Drug: Fentanyl, Drug: Morphine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexmedetomidine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Based Relapse Prevention: Efficacy and Mechanisms
Brief Summary: The broad, long-term objective of the proposed randomized clinical trial is to evaluate the efficacy, moderators and mechanisms of change of two cognitive-behavioral aftercare treatments for alcohol and other drug (AOD) use disorders in preventing AOD relapse compared to treatment as usual (TAU) offered in the community. The two cognitive-behavioral aftercare treatments are relapse prevention (RP) and Mindfulness-Based Relapse Prevention (MBRP), which integrates mindfulness meditation and RP aftercare components.


Options:
A: Arm Label: Introduction to AA volunteer; Type: OTHER; Interventions: Other: Introduction to AA volunteer | Arm Label: AA materials offered; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Introduction to AA volunteer; Assigned to Arm(s): Introduction to AA volunteer
B: Arm Label: Network Support; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Packaged Cognitive-Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Network Support, Packaged Cognitive-Behavioral Treatment
C: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
D: Arm Label: MBRP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Relapse Prevention | Arm Label: Relapse Prevention (RP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relapse Prevention | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Relapse Prevention; Assigned to Arm(s): MBRP | Intervention Type: BEHAVIORAL; Name: Relapse Prevention; Assigned to Arm(s): Relapse Prevention (RP) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual

Answer: D